P/E at 31.1 vs Industry's 37.56: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discounted P/E Amid Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E of 31.10, which is approximately 17% below the Pharmaceuticals & Biotechnology industry average of 37.56. This discount suggests the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be valued more conservatively. Investors might wonder what is the current rating? given this valuation gap and recent performance trends.

Performance Across Timeframes: Mixed Momentum Signals

The stock’s performance over the past year stands at -5.70%, outperforming the Sensex’s -9.19% over the same period. This relative resilience is further highlighted by the year-to-date return of -5.42%, which again surpasses the Sensex’s -13.52%. However, the shorter-term picture is less encouraging. Over the last three months, Dr Reddys Laboratories Ltd has declined by -10.95%, significantly underperforming the Sensex’s -4.41%. This sharp recent weakness contrasts with the positive one-week return of 2.66%, which outpaces the Sensex’s -0.80%, indicating some short-term recovery after a period of decline. The 1-month gain of 0.94% versus the Sensex’s -5.09% further supports this tentative bounce. The 5-day and 20-day moving averages have been breached on the upside, but the stock remains below its 100-day and 200-day averages — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Signs of a Partial Recovery Within a Larger Downtrend

The technical setup for Dr Reddys Laboratories Ltd reveals a nuanced picture. The stock is trading above its 5-day, 20-day, and 50-day moving averages, signalling short-term strength and a possible bounce from recent lows. However, it remains below the 100-day and 200-day moving averages, which typically represent longer-term trend resistance. This configuration often indicates a recovery attempt within a broader downtrend, suggesting that while short-term momentum has improved, the stock has yet to confirm a sustained uptrend. The recent two-day gain following a consecutive fall of the same length further emphasises this tentative rebound. Investors might ask is this a recovery or a dead-cat bounce?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen 28 stocks declare results recently, with 13 posting positive outcomes, 11 flat, and 4 negative. This distribution suggests a broadly stable sector environment with pockets of strength and weakness. Dr Reddys Laboratories Ltd’s performance aligns with this mixed sector backdrop, neither leading nor lagging dramatically. The sector’s average P/E of 37.56 reflects investor optimism, yet the stock’s valuation discount and recent performance divergence highlight a more cautious stance. This raises the question should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a new assessment. The previous Mojo Score stood at 36.0, reflecting a cautious outlook. This reassessment coincides with the stock’s valuation discount relative to the sector and its mixed performance across timeframes. The data suggests a nuanced stance, balancing short-term recovery signs against longer-term challenges. The question remains what is the current rating? in light of these factors.

Conclusion: A Complex Picture of Valuation and Momentum

The data on Dr Reddys Laboratories Ltd paints a complex picture. The stock trades at a meaningful discount to its sector’s P/E, suggesting market caution despite a relatively resilient one-year performance. Short-term momentum shows signs of recovery, with gains over the past week and month, yet the three-month decline and position below long-term moving averages indicate ongoing challenges. Sector results are mixed, reflecting a broader environment of uncertainty. The recent rating reassessment from Hold adds another layer of complexity, underscoring the need for investors to carefully weigh valuation against technical signals. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →